MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.15

-0.3%

Nov 3 1:15 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/4/2008 2:14:52 AM
	of 2240

Additional immune checkpoints in prostate cancer: PD-1 and LAG-3 Wednesday, 3 December 2008 - At the Prostate Cancer Foundation (PCF) 15th Annual Scientific Retreat held at Incline Village, Nevada, USA, Dr. Charles Drake from Johns Hopkins presented new information on immune checkpoints that may present additional therapeutic opportunities. According to Drake, directing the immune system to eradicate prostate cancer from patients may require more than one approach. During the conference, Drake and Drs. James Allison, program chairman of the Immunology Institute at Memorial Sloan-Kettering Cancer Centre, also discussed basic science findings suggesting several checkpoints that can be therapeutically blocked in prostate cancer patients to allow the immune system to attack metastatic prostate cancer cells. These checkpoint genes include PD-1, LAG-3, and others in the B7-X family. Drake reviewed data from a Phase I trial he has concluded for PD-1 checkpoint inhibition using a monoclonal antibody. He observed clinical responses without serious side effects. Side effect profiles will also be fully investigated by dose escalation. The PCF said it will be carefully tracking the results of immunotherapy clinical trials and emerging checkpoint biology research in the coming months. The key findings discussed by Dr. Drake were: • Prostate cancer is infiltrated with specific T cells that are biologically blocked from killing tumours by a newly discovered resistance molecule named PD-1. It is a brake or checkpoint of the immune system that prevents the immune system from attacking tumour cells. • Phase I Trial of PD-1 blocking antibody is completed. • The blocking antibody was relatively well-tolerated and evidence of immune activity was demonstrated. • Checkpoint blockade with vaccination will be studies in future investigations. • LAG-3 is another immune checkpoint that is being studied for its role in hiding prostate cancer cells from the immune system. urosource.com[backPid]=460&cHash=463a7919db

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next